Hasin DS, Sarvet AL, Meyers JL, et al. Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States. JAMA Psychiatry. 2018;75(4):336–46. https://doi.org/10.1001/jamapsychiatry.2017.4602.
Article PubMed Central Google Scholar
GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2017;392(10159):1789–858. https://doi.org/10.1016/s0140-6736(18)32279-7.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington: American Psychiatric Publishing; 2013.
Franken IH, Rassin E, Muris P. The assessment of anhedonia in clinical and non-clinical populations: further validation of the Snaith–Hamilton Pleasure Scale (SHAPS). J Affect Disord. 2007;99(1–3):83–9. https://doi.org/10.1016/j.jad.2006.08.020.
Baune BT, Florea I, Ebert B, et al. Patient expectations and experiences of antidepressant therapy for major depressive disorder: a qualitative study. Neuropsychiatr Dis Treat. 2021;17:2995–3006. https://doi.org/10.2147/ndt.S325954.
Article PubMed Central Google Scholar
Arnaud AM, Brister TS, Duckworth K, et al. Impact of major depressive disorder on comorbidities: a systematic literature review. J Clin Psychiatry. 2022;83(6):43390. https://doi.org/10.4088/JCP.21r14328.
Moitra M, Santomauro D, Degenhardt L, et al. Estimating the risk of suicide associated with mental disorders: a systematic review and meta-regression analysis. J Psychiatr Res. 2021;137:242–9. https://doi.org/10.1016/j.jpsychires.2021.02.053.
Article PubMed Central Google Scholar
Chesney E, Goodwin GM, Fazel S. Risks of all-cause and suicide mortality in mental disorders: a meta-review. World Psychiatry. 2014;13(2):153–60. https://doi.org/10.1002/wps.20128.
Article PubMed Central Google Scholar
McIntyre RS, Filteau M-J, Martin L, et al. Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. J Affect Disord. 2014;156:1–7. https://doi.org/10.1016/j.jad.2013.10.043.
Qaseem A, Barry MJ, Kansagara D, et al. Nonpharmacologic versus pharmacologic treatment of adult patients with major depressive disorder: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2016;164(5):350–9. https://doi.org/10.7326/M15-2570.
American Psychological Association. APA clinical practice guideline for the treatment of depression across three age cohorts. 2019. https://www.apa.org/depression-guideline/guideline.pdf. Accessed 18 Sept 2023.
US Department of Veterans Affairs. VA/DOD clinical practice guideline for the management of major depressive disorder. 2022. 4.0. https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf. Accessed 18 Sept 2023.
Machado-Vieira R, Henter ID, Zarate CA Jr. New targets for rapid antidepressant action. Prog Neurobiol. 2017;152:21–37. https://doi.org/10.1016/j.pneurobio.2015.12.001.
Henter ID, Park LT, Zarate CA Jr. Novel glutamatergic modulators for the treatment of mood disorders: current status. CNS Drugs. 2021;35(5):527–43. https://doi.org/10.1007/s40263-021-00816-x.
Article CAS PubMed Central Google Scholar
Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28–40. https://doi.org/10.1176/appi.ajp.163.1.28.
Huynh NN, McIntyre RS. What are the implications of the STAR*D trial for primary care? A review and synthesis. Prim Care Companion J Clin Psychiatry. 2008;10(2):91. https://doi.org/10.4088/pcc.v10n0201.
Article PubMed Central Google Scholar
McIntyre RS, Alsuwaidan M, Baune BT, et al. Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry. 2023;22(3):394–412. https://doi.org/10.1002/wps.21120.
Article PubMed Central Google Scholar
Pigott HE, Kim T, Xu C, et al. What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapies in real-world depressed patients? A reanalysis of the STAR*D study’s patient-level data with fidelity to the original research protocol. BMJ Open. 2023;13(7): e063095. https://doi.org/10.1136/bmjopen-2022-063095.
Article PubMed Central Google Scholar
Gadad BS, Jha MK, Czysz A, et al. Peripheral biomarkers of major depression and antidepressant treatment response: current knowledge and future outlooks. J Affect Disord. 2018;233:3–14. https://doi.org/10.1016/j.jad.2017.07.001.
Orsolini L, Pompili S, Tempia Valenta S, et al. C-reactive protein as a biomarker for major depressive disorder? Int J Mol Sci. 2022;23(3):1616. https://doi.org/10.3390/ijms23031616.
Article CAS PubMed Central Google Scholar
Stahl SM. Dextromethorphan/bupropion: a novel oral nmda (N-methyl-d-aspartate) receptor antagonist with multimodal activity. CNS Spectr. 2019;24(5):461–6. https://doi.org/10.1017/S1092852919001470.
Sim K, Lau WK, Sim J, et al. Prevention of relapse and recurrence in adults with major depressive disorder: systematic review and meta-analyses of controlled trials. Int J Neuropsychopharmacol. 2016;19(2):pyv076. https://doi.org/10.1093/ijnp/pyv076.
Burcusa SL, Iacono WG. Risk for recurrence in depression. Clin Psychol Rev. 2007;27(8):959–85. https://doi.org/10.1016/j.cpr.2007.02.005.
Article PubMed Central Google Scholar
Touya M, Lawrence DF, Kangethe A, et al. Incremental burden of relapse in patients with major depressive disorder: a real-world, retrospective cohort study using claims data. BMC Psychiatry. 2022;22(1):152. https://doi.org/10.1186/s12888-022-03793-7.
Article PubMed Central Google Scholar
Almohammed OA, Alsalem AA, Almangour AA, et al. Antidepressants and health-related quality of life (HRQOL) for patients with depression: analysis of the Medical Expenditure Panel Survey from the United States. PLoS One. 2022;17(4): e0265928. https://doi.org/10.1371/journal.pone.0265928.
Saragoussi D, Christensen MC, Hammer-Helmich L, et al. Long-term follow-up on health-related quality of life in major depressive disorder: a 2-year European cohort study. Neuropsychiatr Dis Treat. 2018. https://doi.org/10.2147/NDT.S159276.
Article PubMed Central Google Scholar
IsHak WW, Mirocha J, James D, et al. Quality of life in major depressive disorder before/after multiple steps of treatment and one-year follow-up. Acta Psychiatr Scand. 2015;131(1):51–60. https://doi.org/10.1111/acps.12301.
Costanza A, Vasileios C, Ambrosetti J, et al. Demoralization in suicide: a systematic review. J Psychosom Res. 2022;157: 110788. https://doi.org/10.1016/j.jpsychores.2022.110788.
Berardelli I, Serafini G, Cortese N, et al. The involvement of hypothalamus–pituitary–adrenal (hpa) axis in suicide risk. Brain Sci. 2020;10(9):653. https://doi.org/10.3390/brainsci10090653.
Article CAS PubMed Central Google Scholar
Zhdanava M, Pilon D, Ghelerter I, et al. The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States. J Clin Psychiatry. 2021;82(2):29169. https://doi.org/10.4088/JCP.20m13699.
Fava GA, Offidani E. The mechanisms of tolerance in antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(7):1593–602. https://doi.org/10.1016/j.pnpbp.2010.07.026.
Andrews PW, Amsterdam JD. A hormetic approach to understanding antidepressant effectiveness and the development of antidepressant tolerance—a conceptual view. Psychiatr Polska. 2020;11:78. https://doi.org/10.12740/PP/120084.
Jaffe DH, Rive B, Denee TR. The humanistic and economic burden of treatment-resistant depression in Europe: a cross-sectional study. BMC Psychiatry. 2019;19:1–11. https://doi.org/10.1186/s12888-019-2222-4.
Rossom RC, Shortreed S, Coleman KJ, et al. Antidepressant adherence across diverse populations and healthcare settings. Depress Anxiety. 2016;33(8):765–74. https://doi.org/10.1002/da.22532.
Article CAS PubMed Central Google Scholar
Pillinger T, Howes OD, Correll CU, et al. Antidepressant and antipsychotic side-effects and personalised prescribing: a systematic review and digital tool development. Lancet Psychiatry. 2023;10(11):860–76. https://doi.org/10.1016/S2215-0366(23)00262-6.
Comments (0)